Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 6 455 JPY 0.23% Market Closed
Market Cap: ¥485.2B

Net Margin

12.6%
Current
Improving
by 1.6%
vs 3-y average of 11%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.6%
=
Net Income
¥20B
/
Revenue
¥159.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.6%
=
Net Income
¥20B
/
Revenue
¥159.3B

Peer Comparison

Country Company Market Cap Net
Margin
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
452.3B JPY
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

Higher than 82% of companies in Japan
Percentile
82st
Based on 6 917 companies
82st percentile
12.6%
Low
-122 700% — 2.9%
Typical Range
2.9% — 8.5%
High
8.5% — 63 031.4%
Distribution Statistics
Japan
Min -122 700%
30th Percentile 2.9%
Median 5.4%
70th Percentile 8.5%
Max 63 031.4%

Hisamitsu Pharmaceutical Co Inc
Glance View

Market Cap
485.2B JPY
Industry
Pharmaceuticals

In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.

Hisamitsu Pharmaceutical Co Inc Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
12.6%
=
Net Income
¥20B
/
Revenue
¥159.3B
What is Hisamitsu Pharmaceutical Co Inc's current Net Margin?

The current Net Margin for Hisamitsu Pharmaceutical Co Inc is 12.6%, which is above its 3-year median of 11%.

How has Net Margin changed over time?

Over the last 3 years, Hisamitsu Pharmaceutical Co Inc’s Net Margin has increased from 10.3% to 12.6%. During this period, it reached a low of 9.2% on Feb 28, 2023 and a high of 13.9% on Feb 28, 2025.

Back to Top